• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Life Sciences | News, Analysis, Insights - HIT Consultant

Eyenovia Secures $15M for Ophthalmic Drug Delivery Technologies

by Jasmine Pennic 11/29/2022 Leave a Comment

Eyenovia Secures $15M for Ophthalmic Drug Delivery Technologies

What You Should Know: - Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company enters a $15M credit facility with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”). - The financing is
Read More

Summer Health Launches Messaging-Based Pediatric Care to Combat the RSV, Flu, and COVID Tripledemic

by Syed Hamza Sohail 11/29/2022 Leave a Comment

Summer Health Launches Messaging-Based Pediatric Care to Combat the RSV, Flu, and COVID Tripledemic

What You Should Know: - Summer Health, the first text-based pediatric care provider designed to offer parents support, prescriptions, and referrals within just 15 minutes, today launched free trials to combat the U.S. tripledemic plagued by the rise of RSV, Flu, and COVID cases amongst children. - Amid a growing pediatric-care crisis that has caused an overflow in emergency rooms and doctor’s offices across the country, Summer Health aims to help relieve the overwhelming burden and be the
Read More

RSNA: Flywheel Builds Data Platform for Unbiased Breast Imaging AI

by Fred Pennic 11/28/2022 Leave a Comment

Flywheel Builds Data Platform for Unbiased Breast Imaging AI

What You Should Know: - Today, at RSNA, Flywheel, a leading data management platform for biomedical research and collaboration announces the creation of a federated data platform for the development of unbiased breast imaging AI. - Funded in part by the NIH, the federated network will support breast imaging AI research and collaboration—on a scale not previously possible. Leveraging Flywheel Discovery & Exchange Two Flywheel technologies underpin the project. Flywheel
Read More

What Has COVID Ever Done For Us? Here 9 Examples

by Ivor Campbell, CEO of Snedden Campbell, 11/23/2022 Leave a Comment

What Has COVID Ever Done For Us?

The early 2020s will be studied by historians as a time of global uncertainty when an unknown pathogen caused a public health emergency that brought the world to the brink. It may also be remembered as a time of unparalleled cooperation and advancement in technologies, prompted by the Covid pandemic, that provided enduring benefits for generations to come. Just as the two world wars of the 20th Century were the deadliest and most attritional in history, they also triggered developments in
Read More

Site Enablement Platforms Can Accelerate Clinical Trials by 6  Weeks and Reduce Costs by Over $1M

by Syed Hamza Sohail 11/23/2022 Leave a Comment

Site Enablement Platforms Can Accelerate Clinical Trials by 6 Weeks and Reduce Costs by Over $1M

What You Should Know: - Florence HealthcareTM, a clinical research technology company headquartered in Atlanta, Georgia, recently announced the completion of a year-long third-party study on the impact of Site Enablement PlatformsTM on clinical research timelines and costs.  - The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor
Read More

Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech

by Fred Pennic 11/16/2022 Leave a Comment

Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech

What You Should Know:   - Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More

Patent Awarded for Saliva-Based Test to Help Diagnose Concussion

by Fred Pennic 11/16/2022 Leave a Comment

Patent Awarded for Saliva-Based Test to Help Diagnose Concussion

What You Should Know: - Quadrant Biosciences announced today that the U.S. Patent and Trademark Office (USPTO) has awarded the company and two of its academic partners, the State University of New York Research Foundation and the Penn State Research Foundation, with U.S. Patent No.11,453,914 for the analysis and prediction of mild traumatic brain injury (mTBI) and concussion symptoms. - This research was first mentioned on CNN back in 2017.
Read More

HLTH22: Cyclica Awarded $1.8M Grant from Bill & Melinda Gates Foundation to Discover Non-Hormonal Contraceptive

by Syed Hamza Sohail 11/15/2022 Leave a Comment

Cyclica Teams with Bill & Melinda Gates Foundation to Discover Non-Hormonal Contraceptive

What You Should Know: - Cyclica Inc., a neo-biotech that is exploring the entire protein universe to advance a robust and sustainable drug discovery portfolio, has received a $2.4M CAD ($1.8M USD) grant from the Bill & Melinda Gates Foundation to develop new, non-hormonal contraceptives for low-data biological protein targets. - The grant enables Cyclica to apply its validated, AI-enabled drug discovery platform towards the discovery of expanded contraceptive options that can give
Read More

HLTH22: Curavit Raises $5M for Digital Therapeutics Clinical Research

by Fred Pennic 11/14/2022 Leave a Comment

Curavit Raises $5M for Digital Therapeutics Clinical Research

What You Should Know: - Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) announced it raised $5M in Series A funding to accelerate its growing portfolio of research in the global digital therapeutics (DTx) market. The round was led by  Osage Venture Partners with additional investment from Royal Street Ventures and Narrow Gauge Ventures.  - The new funding will be used to expand
Read More

Should I Get Another Booster? How Doctors Can Help Patients Navigate the Next Phase of COVID-19

by Dr. Joe Nicholson, Chief Medical Officer at CareAllies 11/14/2022 Leave a Comment

Should I Get Another Booster? How Doctors Can Help Patients Navigate the Next Phase of COVID-19

The general consensus is that COVID-19 in some form is here to stay. As people come to terms with this reality, primary care providers may be getting more questions from patients – especially older and immunocompromised ones – asking for advice on how to handle different situations. Should I get another booster? Can I start traveling? Is it OK to go to a wedding next weekend? How cautious do I need to be in social settings? The answers to these questions aren’t always clear. A lot depends on
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 46
  • Go to page 47
  • Go to page 48
  • Go to page 49
  • Go to page 50
  • Interim pages omitted …
  • Go to page 85
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |